Markets and Stocks January 2023 – Doc Holliday talks to Alan Green

Markets and Stocks January 2023 – Doc Holliday talks to Alan Green. We look at Doc’s new Twitter Spaces cast, before turning to stocks: 04:00 Avacta #AVCT | 06:00 Hvivo #HVO & Poolbeg Pharma #POLB | 08:15 – Longboat Energy #LBE / Energy stocks | 11:26 – Cadence Minerals #KDNC | 14:55 – Mining Companies | […]

Markets and Stocks – Doc Holliday talks to Alan Green

As we head towards Christmas, Alan Green and Doc Holliday talk markets and stocks. We discuss the macro events in the UK and the opportunities that Brexit and inflation could be throwing up for UK agriculture before we turn to stocks. Doc covers Harland & Wolff #HARL, ECR Minerals #ECR, Contango Holdings #CGO, Emmerson #EML, […]

#HVO hVIVO plc- Share Price

hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, saw the share price rise which was then picked up in the Daily Mail Stock Watch this morning   For further information please contact: […]

hVIVO #HVO – Major Shareholding

hVIVO #HVI TR-1: Standard form for notification of major holdings Allan Rankin now owns 20,702,209 shares (3.09%) of HVO issued share capital

Open Orphan #ORPH – Change of name to hVIVO plc effective

Open Orphan #ORPH, a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to its announcement on 8 September 2022, the Company’s change of name to hVIVO plc (AIM: HVO) has now been completed and is expected to take […]

Open Orphan #ORPH – CFO appointment & change of Board roles

Open Orphan #ORPH (to be renamed hVIVO plc (Ticker: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Stephen Pinkerton as Chief Financial Officer (“CFO”) and as an Executive Director, effective with immediate […]